 |
Top 100 medical and healthcare startups in UK
Oct 04, 2025 | By Jason Kwon | 16 |
1
Funding: $21M
Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders.
Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders.
2
Funding: £7M
Healthera is a provider of next-generation, pharmacy-integrated personal health management solutions.
Healthera is a provider of next-generation, pharmacy-integrated personal health management solutions.
3
Funding: $192.5M
PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
4
Funding: $130.7M
Numan is a startup which aims to tackle your tackle problem erectile dysfunction.
Numan is a startup which aims to tackle your tackle problem erectile dysfunction.
5
Funding: £20.7M
Sano Genetics is a personalised medicine research platform with data privacy and transparency at its core.
Sano Genetics is a personalised medicine research platform with data privacy and transparency at its core.
6
Funding: £16.6M
Collective Benefits provides benefits that matter for the self-employed that make it easy for companies to attract, retain and reward self-employed workforces
Collective Benefits provides benefits that matter for the self-employed that make it easy for companies to attract, retain and reward self-employed workforces
7
Funding: $18.5M
uMed is a technology platform embedded within a global network of healthcare providers that automates the process of building high quality prospective research registries
uMed is a technology platform embedded within a global network of healthcare providers that automates the process of building high quality prospective research registries
8
Funding: $17.1M
MediShout is a digital solution that connects healthcare teams and improves operational efficiency, so staff can provide better care.
MediShout is a digital solution that connects healthcare teams and improves operational efficiency, so staff can provide better care.
9
Funding: £12.5M
Shift Bioscience is creating new drug targets and diagnostic tools to enhance healthy lifespan through the repair of mitochondrial genes that cause neurodegenerative diseases or coronary heart disease.
Shift Bioscience is creating new drug targets and diagnostic tools to enhance healthy lifespan through the repair of mitochondrial genes that cause neurodegenerative diseases or coronary heart disease.
10
Funding: $11.5M
PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.
PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.
12
Funding: £6.2M
Zetta Genomics manages large-scale genomic data for precision medicine.
Zetta Genomics manages large-scale genomic data for precision medicine.
13
Funding: £1.5M
Cell Guidance Systems is a biotechnology company developing research tools for stem cell technology.
Cell Guidance Systems is a biotechnology company developing research tools for stem cell technology.
14
Funding: £1.1B
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
15
Funding: $1.2B
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
16
Funding: $1.2B
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
17
Funding: $1.2B
babylon was founded with a single purpose: To put an accessible and affordable health service in the hands of every person on earth. How? We’ll do this by combining the ever growing computing power of machines, with the best medical expertise of humans to create a comprehensive, immediate and personalized health service and making it universally available.
babylon was founded with a single purpose: To put an accessible and affordable health service in the hands of every person on earth. How? We’ll do this by combining the ever growing computing power of machines, with the best medical expertise of humans to create a comprehensive, immediate and personalized health service and making it universally available.
18
Funding: $1.1B
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
19
Funding: $1.1B
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
20
Funding: $1.1B
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
